Clinical, diagnostic, and treatment comparisons between Stevens-Johnson syndrome and toxic epidermal necrolysis: review of the literature
Main Article Content
Abstract
Stevens-Johnson syndrome is a rare but serious medical condition, which is classified within the blistering diseases of the skin and mucous membranes. It is characterized by a severe and generalized immune-mediated inflammatory reaction, predominantly affecting the skin and mucous membranes, such as the eyes, mouth and genitalia.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56:181-200
II. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6.
III. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922;¿Volumen?:526-32.
IV. 4. Lyell A. Toxic epidermal necrolysis: An eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-61.
V. 5. French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Allergology International. 2006;55:9-16.
VI. 6. Whorl S, Loewe R, Pickl WF, Stingl G, Wagner SN. EMPACT syndrome. Dtsch Dermatol Ges. 2005;3:39-43.
VII. 7. Sharma VK, Sethuraman G, Minz A. Stevens-Johnson syndrome, toxic epidermal necrolysis, and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008;74:238-40.
VIII. 8. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal anti-inflammatory drugs: A multinational perspective. J Rheumatol. 2003;30:2234-40.
IX. 9. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7:142-60.
X. 10. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol. 2008;128:35-44.
XI. 11. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-8.
XII. 12. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case control study. Lancet. 1999;353:2190.
XIII. 13. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: Reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20:219-23.
XIV. 14. Chung WH, Hung SI, Hsih MS, Yang LC, Ho HC, Wu JY, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
XV. 15. Yang CW, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, et al. HLA-B*1502-bound peptides: Implications for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2007;120:870-7.
XVI. 16. Laguna C, Martín B, Torrijos A, García-Melgares ML, Febrer I. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical experience and review of the specialized literature. Actas Dermosifiliogr. 2006;97:177-85.
XVII. 17. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3.
XVIII. 18. Viard-Leveugle I, Bullani RR, Meda P, Micheau O, Limat A, Saurat JH, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem. 2003;278:16183-8.
XIX. 19. Parrillo SP. Stevens-Johnson syndrome and toxic epidermal necrolysis. Current Allergy and Asthma Reports. 2007;7:243-7.
XX. 20. Bolognia JL, Jorizzo J, Rapini R. United States of America. Elsevier. Dermatology. 2nd edition. Madrid, Spain: Elsevier; 2008. p. 287-300.
XXI. 21. Léauté-Labrèze C, Lamireau T, Chawki D, Maleville J, Taïeb A. Diagnosis, classification and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83:347-52.
XXII. 22. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-7.
XXIII. 23. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimarães J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207:33-6.
XXIV. 24. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med. 1994;331:1272-85. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin. 2000;18:485-95.
XXV. Crosi A, Borges S, Estévez F. Serious adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Med Uruguay. 2004;20:172-7.
XXVI. 27. Vanfleteren I, VanGysel D, DeBrandt C. Stevens-Johnson syndrome: A diagnostic challenge in the absence of skin lesions. Ped Dermatol. 2003;20:152-6.
XXVII. 28. Sheridan RL, Liu V, Anupindi S. Case 34-2005: A 10-year-old girl with a bullous skin eruption and acute respiratory failure. N Engl J Med. 2005;353:2057-66.
XXVIII. 29. Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141:683-7.